Table II.
Invasiveness | Univariate analysis | |||
---|---|---|---|---|
Variable | Yes (n=15) | No (n=37) | χ2 | P-value |
Age, years | 2.342 | 0.126 | ||
≤40.3 | 10 | 16 | ||
>40.3 | 5 | 21 | ||
Sex | 0.843 | 0.358 | ||
Male | 9 | 17 | ||
Female | 6 | 20 | ||
Tumor size, cm3 | 5.996 | 0.014 | ||
≤6.25 | 12 | 14 | ||
>6.25 | 3 | 23 | ||
GH level, ng/ml | 36.7±11.9 | 17.2±6.3 | – | <0.05 |
Resection | 4.611 | 0.032 | ||
Total | 5 | 26 | ||
Partial | 10 | 11 | ||
Recurrence | 4.489 | 0.034 | ||
Yes | 6 | 5 | ||
No | 9 | 37 | ||
SLC20A1 | 7.589 | 0.006 | ||
Higha | 12 | 14 | ||
Low | 3 | 23 | ||
Wif1 | 9.369 | 0.002 | ||
High | 2 | 24 | ||
Low | 13 | 13 | ||
β-catenin | 4.591 | 0.032 | ||
High | 11 | 15 | ||
Low | 4 | 22 |
High, positive percentage of SLC20A1, Wif1 or β-catenin is ≥50%; low, positive percentage of SLC20A1, Wif1 or β-catenin <50%. GH, growth hormone; SLC20A1, solute carrier family 20 member 1; Wif1, Wnt inhibitory factor 1.